Welcome to our dedicated page for Fresenius Med Cr SEC filings (Ticker: FMCQF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for FRESENIUS MED CARE AG ORD (FMCQF) on Stock Titan provides access to regulatory documents that Fresenius Medical Care AG submits as a foreign private issuer. The company files annual reports under Form 20-F and furnishes interim information on Form 6-K under the Securities Exchange Act of 1934.
Form 6-K filings for Fresenius Medical Care AG frequently include exhibits such as press releases announcing quarterly results and detailed financial overviews for specified periods. One example described in the filings is a press release for third quarter results accompanied by a complete overview of performance for that quarter and the first nine months of the year. Other 6-K reports furnish information disclosed under the EU Market Abuse Regulation, as well as press releases dated on particular days.
In its filings, the company notes that it prepares consolidated financial results in accordance with IFRS and supplements these with non-GAAP financial measures. These measures include EBITDA, free cash flow, a net leverage ratio and results presented in constant currency or adjusted for special items. The filings explain that reconciliations from these non-GAAP figures to the most comparable IFRS measures are included in the attached financial statements or tables.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to interpret the technical language. The platform highlights key elements from Form 6-K and Form 20-F reports, helping readers understand segment references such as Health Care Services, Health Care Products, Value Based Care, Care Delivery and Care Enablement, as well as disclosures about non-GAAP metrics and their reconciliations.
Investors interested in FMCQF can use this page to locate the latest 6-K submissions, annual 20-F reports and related exhibits, and to see how Fresenius Medical Care AG presents its financial performance and regulatory disclosures over time.
Fresenius Medical Care AG filed an initial Form 3 for officer Olga Renkewitsch, indicating her status as an executive (title referenced as “See Remarks”). The provided data show no reported transactions, no derivative positions, and no specific share holdings, serving mainly as a baseline ownership disclosure.
Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.
The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.
Fresenius Medical Care AG files its annual Form 20-F, outlining its global kidney care business and risk profile. The company reports 279,288,885 ordinary shares outstanding as of the period end, and notes that Fresenius SE held 76,814,594 shares, or 26.2%, as of February 13, 2026.
The report explains a three-segment structure: Care Enablement (products and manufacturing), Care Delivery (dialysis and related services), and a new Value-Based Care segment created June 1, 2025, which manages risk-based kidney care contracts under IFRS 15 and IFRS 17. It also describes the 2023 legal conversion from a partnership limited by shares into a stock corporation and Fresenius SE’s ongoing influence via board appointment rights and trademark licensing.
Extensive risk disclosures highlight dependence on U.S. Medicare and Medicaid (Medicare and Medicaid contributed about 16% of consolidated revenue in 2025, with additional Medicaid and other government sources representing 4.7% of U.S. patient service revenue), exposure to healthcare reform and reimbursement cuts, regulatory and compliance requirements, cyber-security threats, ESG and supply-chain obligations, labor shortages, macroeconomic pressures, and €10,795 M of consolidated debt versus €14,283 M of shareholders’ equity as of December 31, 2025.
Fresenius Medical Care reported a strong 2025, with revenue of €19.6 billion and operating income up 31% to €1.83 billion. On an adjusted basis, operating income rose 23% to €2.21 billion, lifting the margin to 11.3% from 9.3%.
Net income attributable to shareholders jumped 82% to €978 million, and adjusted net income rose 38% to €1.25 billion. Basic EPS increased to €3.36, or €4.28 excluding special items. Operating cash flow grew 12% to €2.68 billion and free cash flow reached €1.78 billion.
The company cut net debt to €9.2 billion and reduced its net leverage ratio to 2.5x. Management proposes a €1.49 dividend per share, about 33% of adjusted net income, and is executing a €1.0 billion share buyback while targeting further FME25+ cost savings and modest operating income growth through 2028.
Humacyte, Inc. received an updated Schedule 13D/A showing that Fresenius Medical Care Holdings, Inc. (FMCH) beneficially owns 18,312,735 shares of Humacyte common stock, representing about 9.5% of the outstanding voting shares. This percentage is based on 192,996,511 shares outstanding as of December 15, 2025. The filing explains that the stake declined from 9.9% to 9.5% solely because Humacyte’s total shares outstanding increased; FMCH and its parent Fresenius Medical Care AG (FME AG) have neither bought nor sold Humacyte shares since their initial Schedule 13D in 2021. All 18,312,735 shares are issued, outstanding, and owned directly by FMCH, while FME AG may be deemed an indirect beneficial owner through its ownership of FMCH. The amendment also notes board and management changes at FME AG and FMCH, including new roles for Dr. Charles Hugh-Jones and Joseph E. Turk following the retirement of two prior executives.
Fresenius Medical Care AG reports interim operating updates and segment changes. As of June 1, 2025, the company created a new Value‑Based Care segment, recognizing full‑risk arrangements under IFRS 17 with premiums and claim costs presented separately. For the nine months ended September 30, 2025, 16% of consolidated revenue was attributable to U.S. federally funded programs.
Capital efficiency remained modest: ROIC was 4.1%, or 4.9% excluding Legacy Portfolio Optimization costs, based on NOPAT of €1,101 M and average invested capital of €27,150 M. Total assets were €30,887 M and invested capital €25,471 M as of September 30, 2025.
Regulatory dynamics continue to influence U.S. operations. CMS proposed to terminate the mandatory ETC model on December 31, 2025; 971 U.S. facilities (about 35%) are currently in ETC regions and the program to date produced a net positive payment adjustment. The company participates in 21 KCEs, with approximately 52,000 patients aligned as of September 2025, reflecting scale in value‑based kidney care.